ICML 2025 | Recent updates in the treatment of advanced-stage and early-stage Hodgkin lymphoma

Yeah, there’s really a lot of exciting updates. It seems like almost every few years we keep pushing the curve higher and higher for improved outcomes as well as hopefully quality of life for our Hodgkin lymphoma patients. I was really an honor to have a couple meet the professor sessions here at ICML in beautiful Lugano and really to run through the data on early-stage disease, advanced-stage disease, and also on older patients as well. And for advanced-stage disease, we’ve had a lot of breakthroughs in the last six months. Two really landmark studies published, one in The Lancet, the HD21 BrECADD clinical trial for advanced-stage disease led by the German Hodgkin Study Group. And then S1826, which was led by the U.S. cooperative groups, led by SWOG, included all the adult groups, but also included the Children’s Oncology Group. So that clinical trial included patients 12 years old and above. And both of these really important clinical studies showed that the progression-free survival rate and I would submit really cure rate at least at two and four years is above 90%. 94% for BrECADD at four years and 92% at two years for S1826, which is just remarkable. You know, this was a disease, yes, we knew early on we could cure this in the 1970s, but certainly not at rates above 90% for stage four disease. Pivoting to early-stage, we highlighted, of course, there’s been a lot of plus-minus radiation studies, but really the future also is integrating novel targeted agents like the advanced stage, where the BrECADD introduced brentuximab vedotin, S1826, checkpoint inhibitors to the frontline. Multiple groups across the world are now doing clinical trials to exactly study that. In North America, we have a large Phase III randomized study comparing classic chemotherapy plus/minus radiation versus short course, only two cycles of chemotherapy, and then novel targeted agents with brentuximab vedotin and checkpoint inhibitor. So just a lot of excitement, a lot of just continued breakthroughs for patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.